購(gòu)物車(chē) 
-
Prorenoate potassium
- names：
potassium 3-((4aS,4bS,6aS,7R,9aS,9bR,9cS,10aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10,10a-hexadecahydrocyclopenta[a]cyclopropa[l]phenanthren-7-yl)propanoate
- CAS號(hào)：
49847-97-4
MDL Number： - MF(分子式)： C23H31KO4 MW(分子量)： 410.59
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|
- 大包裝詢(xún)價(jià) 提供各種包裝，敬請(qǐng)垂詢(xún)
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)
| 中文別名 | potassium 3-((4aS,4bS,6aS,7R,9aS,9bR,9cS,10aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10,10a-hexadecahydrocyclopenta[a]cyclopropa[l]phenanthren-7-yl)propanoate |
| 英文別名 | Prorenoate potassium; Sc 23992; Sc-23992; Sc23992; |
| CAS號(hào) | 49847-97-4 |
| Inchi | InChI=1S/C23H32O4.K/c1-21-7-3-13(24)11-18(21)14-12-15(14)20-16(21)4-8-22(2)17(20)5-9-23(22,27)10-6-19(25)26;/h11,14-17,20,27H,3-10,12H2,1-2H3,(H,25,26);/q;+1/p-1/t14-,15-,16+,17+,20-,21+,22+,23-;/m1./s1 |
| InchiKey | NLSAMWIBIQWHTK-TZHLAWPMSA-M |
| 分子式 Formula | C23H31KO4 |
| 分子量 Molecular Weight | 410.59 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲(chǔ)藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說(shuō)明 | Prorenoate potassium(CAS:49847-97-4):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類(lèi)或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Prorenoate potassium is is a synthetic steroidal antimineralocorticoid. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]McInnes GT, Shelton JR, Harrison IR, Perkins RM, Palmer RF. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites. Br J Clin Pharmacol. 1982 Feb;13(2):187-94. PubMed PMID: 7059416; PubMed Central PMCID: PMC1401979. |
| [2]McInnes GT, Harrison IR, Shelton JR, Perkins RM, Clarke JM. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia. Br J Clin Pharmacol. 1984 Aug;18(2):169-74. PubMed PMID: 6487456; PubMed Central PMCID: PMC1463509. |
| [3] Levine D, Ramsay L, Auty R, Branch R, Tidd M. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):381-6. PubMed PMID: 786663. |
| [4] Ramsay LE, Shelton JR, Tidd MJ. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. Br J Clin Pharmacol. 1976 Jun;3(3):475-82. PubMed PMID: 788750; PubMed Central PMCID: PMC2958760. |
| [5] Ramsay L, Harrison I, Shelton J, Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther. 1975 Oct;18(4):391-400. PubMed PMID: 1100306. |
6: McInnes GT, Shelton JR, Harrison IR. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. Clin Pharmacol Ther. 1981 May;29(5):679-86. PubMed PMID: 7214797.7: Lumb GD, Rust JH. The pathologic response of the liver and thyroid of the rat to potassium prorenoate (SC-23992). Toxicol Pathol. 1985;13(4):315-24. PubMed PMID: 3834584.8: Netchitailo P, Delarue C, Perroteau I, Jegou S, Tonon MC, Leroux P, Leboulenger F, Kusmierek MC, Capron MH, Vaudry H. Effect of aldosterone antagonists on mineralocorticoid synthesis in vitro. Inhibition of aldosterone production by prorenoate-K. Eur J Pharmacol. 1982 Feb 5;77(4):243-9. PubMed PMID: 6277668.9: Auty R, Branch RA, Cole EN, Levine D, Ramsay L. Prolactin, diuretics and urinary electrolytes in normal subjects. J Endocrinol. 1976 Aug;70(2):173-81. PubMed PMID: 965879.10: McInnes GT, Shelton JR, Ramsay LE, Harrison IR, Asbury MJ, Clarke JM, Perkins RM, Venning GR. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience. Br J Clin Pharmacol. 1982 Mar;13(3):331-9. PubMed PMID: 6460516; PubMed Central PMCID: PMC1402118.1
對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開(kāi)
SDS 1.0 英文
展開(kāi)
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長(zhǎng)，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
胞插件.png)
細(xì)胞培養(yǎng)耗材技術(shù)領(lǐng)先性
細(xì)胞培養(yǎng)板行業(yè)面臨的核心痛點(diǎn)是：常規(guī)TC處理后表面親水角隨時(shí)間衰減，影響長(zhǎng)期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
胞培養(yǎng)板.jpg)
細(xì)胞培養(yǎng)耗材關(guān)鍵性能
細(xì)胞培養(yǎng)板的水接觸角作為表面潤(rùn)濕性的核心指標(biāo)，直接影響細(xì)胞貼壁、增殖、分化及功能表達(dá)，其中40°（低接觸角/...
2026/4/28 14:52:44
脂.png)
chelex 100樹(shù)脂國(guó)產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹(shù)脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽(yáng)離子的偏好。它對(duì)二價(jià)...
2025/11/4 14:22:46
9月開(kāi)學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái)，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
材料.jpg)
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
